Roche is my take as our NMIBC jv partnerPfizer and Merck seem to have other plans. At least, for what we've seen in their strategic plans recently announced. Doesn't mean the door is completely closed though.
Roche has failed in entering the bladder cancer indication. They would have a golden opportunity to re-enter this important market.
Roche is also in the 3 fields that we're aiming; urology, neurology and pulmonary.
Roche is bigger than Pfizer and Merck.